Longboard pharmaceuticals inc
LBPH 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
LBPH 近期報酬表現
-2.57%
Longboard pharmaceuticals inc
0.98%
同產業平均
0.02%
S&P500
與 LBPH 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PYPD | Polypid ltd | 1 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
NEXI | Neximmune inc | 3 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
TCRT | Alaunos therapeutics inc | 2 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
SHPH | Shuttle pharmaceuticals holdings inc | - | 2 分 | 4 分 | - | 1 分 | |
ELUT | Elutia inc | 2 分 | 2 分 | 4 分 | 1 分 | 1 分 |
- PYPD Polypid ltd價值 1 分趨勢 1 分波段 2 分籌碼 1 分股利 1 分查看更多
LBPH 公司資訊
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.